Mobile

A long-term follow-up study (ZOE-LTFU) of two studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals’ Herpes Zoster subun...

Update Il y a 4 ans
Reference: EUCTR2015-001778-17

A long-term follow-up study (ZOE-LTFU) of two studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine and assessment of 1 or 2 additional doses in two subgroups of older adults

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To assess the Vaccine Efficacy (VE) in the prevention of Herpes Zoster (HZ) over the total duration of the ZOSTER-049 (Z49) study overall as measured by the reduction in HZ risk in subjects ≥50 years of age at the time of first vaccination in the ZOSTER-006/022 (Z6/22) studies.

Inclusion criteria

  • Vaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination)

Links